SCHEMBL2365495

SCHEMBL2365495

O=C(OCc1nccs1)N1CCC(CCOc2ccc(-c3nccs3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 6/20 0.47
ACKR3 P25106 1/20 0.47
GPR119 Q8TDV5 2/20 0.45
HRH2 P25021 4/20 0.41
HRH1 P35367 4/20 0.41
FAAH O00519 1/20 0.41
TEAD1 P28347 1/20 0.41
TEAD3 Q99594 1/20 0.41
LTA4H P09960 2/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
CHEK2 O96017 1/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229417 0.90 GRIN2B (0.52) GRIN2BACKR3HRH2HRH1FAAH
SCHEMBL2230111 0.88 GRIN2B (0.48) GRIN2BGPR119HRH2HRH1FAAH
SCHEMBL13836967 0.88 HRH2 (0.50) GRIN2BGPR119HRH2HRH1MMP2
SCHEMBL2363549 0.88 GRIN2B (0.58) GRIN2BFAAHTEAD1TEAD3MMP2
SCHEMBL2227312 0.87 GRIN2B (0.55) GRIN2BFAAHTEAD1TEAD3LTA4H
SCHEMBL2230044 0.87 GRIN2B (0.46) GRIN2BGPR119FAAHTEAD1TEAD3
SCHEMBL2364772 0.87 GRIN2B (0.46) GRIN2BGPR119HRH2HRH1FAAH
SCHEMBL2227687 0.86 CHEK2 (0.47) GRIN2BGPR119HRH2HRH1FAAH
SCHEMBL2365259 0.86 GRIN2B (0.44) GRIN2BACKR3GPR119HRH2HRH1
SCHEMBL2365505 0.86 GRIN2B (0.44) GRIN2BACKR3GPR119FAAHTEAD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US claimed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP claimed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US claimed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO claimed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 GRIN2B 362/4885ACKR3 1273/4885GPR119 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.